Malignancy-associated hypercalcemia (MAH) occurs due to mechanisms such as PTHrP secretion, osteolytic bone metastases, or excess calcitriol production, and is a key differential diagnosis of PHPT. The gene discussed is PTHLH; the disease is hypercalcemia disease.